Periodicidad semestral: flujo continuo.
ISSN - Electrónico: 2661-6947 / DOI: 10.36015 • LILACS BIREME (19784); LATINDEX (20666)
Laringospasm is one of the most dreaded complications for a pediatric anesthesiologist and it is considered one of the most frequent causes of cardiac arrest in children: its incidence is greater in children who breastfeed. A double blind experiment was carried out where the efficacy of intravenous Lidocaine 2% WO/E administered before extubation (control group) was compared to the administration of the same substance in the induction process as a means of preventing laringospasm. The study included 49 patients older than 6 months and younger than 10 years, males and females and all for oral surgery. Children with high respiratory infections, whose surgery was not oral, patients with two or more intubation attempts and patients, who would require mechanic ventilation after surgery, were excluded from the study. The study group was randomly selected into two groups, Control with 24 patients who were administered Lidocaine 2% WO/E (substance A) before extubation, and the Experimental Group with 25 patients who were administered Lidocaine 2% WO/E (Substance B) during induction. Results: Three cases of laringospasm are linked to the administration of Lidocaine 2% WO/E at induction (p 0.5, RR 1.4) and two cases of laringospasm were linked to the administration of Lidocaine 2% WO/E before extubation (p0.5,RR 0.69). Conclusión: there is no sufficient significant data that indicates that the use of Lidocaine 2% WO/E during induction prevenís laringospasm, nevertheless the study confirms that it does prevent laringospasm when used before extubation.
The authors who publish in this journal accept the following conditions:
1. The authors retain the copyright and grant to the CAMbios MEDICAL-SCIENTIFIC JOURNAL HECAM the right of the first publication, with the work registered with the Creative Commons attribution license, which allows third parties to use the published material provided that they mention the authorship of the work and the first publication in this journal.
2. Authors can make other independent and additional contractual agreements for the non-exclusive distribution of the version of the article published in this journal (for example, include it in an institutional repository or publish it in a book) as long as it clearly indicates that the work was published. for the first time in the CAMbios MEDICAL-SCIENTIFIC JOURNAL HECAM.